Patent ID: 11965036
Assignee: ZYMEWORKS BC INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 0:
1. A method of treating a subject having a HER2 (human epidermal growth factor receptor 2) expressing (HER2+) tumor comprising administering an effective amount of an antigen binding construct to the subject, wherein the antigen binding construct comprises:
a first antigen-binding polypeptide construct which specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) antigen on a HER2-expressing cell, wherein the first antigen binding polypeptide construct comprises a first heavy chain variable region (VH1) and a first light chain variable region (VL1), wherein the VH1 comprises a first complementarity determining region (CDR1) comprising the amino acid sequence shown in SEQ ID NO:348, a second complementarity determining region (CDR2) comprising the amino acid sequence shown in SEQ ID NO:335, and a third complementarity determining region (CDR3) comprising the amino acid sequence shown in SEQ ID NO:336, and the VL1 comprises a CDR1 comprising the amino acid sequence shown in SEQ ID NO:340, a CDR2 comprising the amino acid sequence shown in SEQ ID NO:338, and a CDR3 comprising the amino acid sequence shown in SEQ ID NO:347, wherein the first antigen-binding polypeptide construct comprises a first heavy chain (H1) comprising the VH1 and a first light chain (L1) comprising the VL1, and the first H1 comprises the amino acid sequence shown in SEQ ID NO:97 and the first L1 comprises the amino acid sequence shown in SEQ ID NO:69;
wherein the antigen binding construct further comprises a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, the first Fc polypeptide comprising a first CH3 sequence and the second Fc polypeptide comprising a second CH3 sequence, wherein the first Fc polypeptide is operably linked to the first antigen-binding polypeptide construct.